Silence Therapeutics Plc (SLNCF)
4.00
0.00 (0.00%)
USD |
OTCM |
Sep 01, 16:00
Silence Therapeutics Research and Development Expense (TTM) : 43.54M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 43.54M |
| March 31, 2026 | 50.52M |
| December 31, 2025 | 60.29M |
| September 30, 2025 | 71.27M |
| June 30, 2025 | 67.18M |
| March 31, 2025 | 61.25M |
| September 30, 2024 | 55.45M |
| Date | Value |
|---|---|
| June 30, 2024 | 46.84M |
| March 31, 2024 | 48.76M |
| December 31, 2023 | 54.63M |
| September 30, 2023 | 52.15M |
| June 30, 2023 | 51.17M |
| March 31, 2023 | 48.96M |
| December 31, 2022 | 43.94M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Biodexa Pharmaceuticals Plc | 5.234M |
| NuCana Plc | 12.59M |
| Mereo BioPharma Group Plc | 14.98M |
| Compass Pathways Plc | 112.68M |
| HemoGenyx Pharmaceuticals Plc | -- |